# Lifevantage Corp.

**LFVN**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000849146

# B/C

**on the B/C boundary of 370 graded peers in healthcare**

rank 153 of 370; percentile 41.2; sampling error 2.5 points; lower is stronger

A B C D E

**B/C, the elk**



| Scoreboard | |
|---|---|
| **Profitability** | B<br>percentile 24.0 |
| **Solvency** | C/D<br>percentile 58.6 |
| **Growth and financing** | C<br>percentile 55.4 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $62.1M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: short runway, distress, fortress balance sheet |
| **Inputs computable** | 10 of 14 |
| **Graded from** | filings received through Aug 27, 2026<br>59 days before the rescan; latest periodic filing 10-K received Aug 27, 2026 |
| **Last close** | $5.73<br>2026-10-23; market equity $71.8M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Aug 27, 2026*

LifeVantage Corporation (the "Company," "LifeVantage," "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 24.0** | | | | | | |
| Gross profitability | 228.0% | 32.3% | | 0.8 | 368 | 2026-06-30 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (7.7%) | (6.6%) | | 50.9 | 807 | 2026-06-30 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Gross margin stability, five years | 1.3 pts | 2.8 pts | 20.3 | 242 | 2026-06-30 |
| **Solvency, sleeve percentile 58.6** | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | (1.63) | (0.33) | 43.9 | 752 | 2026-06-30 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2024-06-30; latest annual assets end 2026-06-30* | | | | | |
| Current ratio | 1.89x | 2.94x | 73.3 | 834 | 2026-06-30 |
| **Growth and financing, sleeve percentile 55.4** | | | | | |
| Revenue growth, three-year compound | (5.1%) | 10.1% | 79.9 | 413 | 2026-06-30 |
| Free cash flow growth, three-year compound | 21.0% | 10.9% | 42.1 | 96 | 2026-06-30 |
| Reinvestment rate | (94.3%) | 37.1% | 90.3 | 104 | 2026-06-30 |
| Asset growth, three years | (2.1%) | 2.1% | 56.7 | 700 | 2026-06-30 |
| Net share issuance, one year | (1.3%) | 2.5% | 8.2 | 636 | 2026-08-26 |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 148 | National Healthcare Corp. (NHC) | 39.8 | B/C | fortress balance sheet |
| 149 | Shattuck Labs, Inc. (STTK) | 40.1 | B/C | dilution |
| 150 | ImmunityBio, Inc. (IBRX) | 40.4 | B/C | short runway |
| 151 | Celldex Therapeutics, Inc. (CLDX) | 40.7 | B/C | short runway |
| 152 | Myomo, Inc. (MYO) | 40.9 | B/C | fortress balance sheet |
| 153 | Lifevantage Corp. (LFVN) | 41.2 | B/C | |
| 154 | Xeris Biopharma Holdings, Inc. (XERS) | 41.5 | B/C | |
| 155 | Envista Holdings Corp. (NVST) | 41.7 | B/C | |
| 156 | Sight Sciences, Inc. (SGHT) | 42.0 | B/C | fortress balance sheet |
| 157 | Repligen Corp. (RGEN) | 42.3 | B/C | late filer, fortress balance sheet |
| 158 | Community Health Systems Inc. (CYH) | 42.5 | C | |

## What the price implies

*at the 2026-10-23 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (34.0%) | 7.7% | 21 |
| Distance from 52-week high | (45.2%) | (31.4%) | 31 |
| EBIT to enterprise value | 6.5% | (1.5%) | 85 |
| Free cash flow yield | 9.1% | (1.0%) | 90 |
| Book value to price | 0.46 | 0.28 | 65 |
| Sales to price | 2.49 | 0.30 | 93 |
| Composite equity issuance, five years | (23.9%) | 20.5% | 5 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Relative strength against the sector, log excess return | (0.63) | (0.14) | 21 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2026-06-30** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 59 (10-K received Aug 27, 2026) |
| Median daily dollar volume, 63 sessions | $265,371 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $141.6M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 2 | assets | us-gaap:Assets | $62.1M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 3 | net income | us-gaap:NetIncomeLoss | $5.1M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $10.2M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 5 | assets | us-gaap:Assets | $72.0M | 2025-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 6 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $182.6M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 7 | gross profit | us-gaap:GrossProfit | $183.7M | 2025-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $228.5M | 2025-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 9 | gross profit | us-gaap:GrossProfit | $158.7M | 2024-06-30 | 2025-09-04 | 10-K | 25-000068 |
| 10 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $200.2M | 2024-06-30 | 2025-09-04 | 10-K | 25-000068 |
| 11 | gross profit | us-gaap:GrossProfit | $170.0M | 2023-06-30 | 2024-08-28 | 10-K | 24-000073 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $213.4M | 2023-06-30 | 2024-08-28 | 10-K | 24-000073 |
| 13 | gross profit | us-gaap:GrossProfit | $168.3M | 2022-06-30 | 2023-08-28 | 10-K | 23-000102 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $206.4M | 2022-06-30 | 2023-08-28 | 10-K | 23-000102 |
| 15 | current assets | us-gaap:AssetsCurrent | $38.3M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $20.2M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$103.5M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | $6.1M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 19 | book equity | us-gaap:StockholdersEquity | $33.6M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 20 | liabilities | us-gaap:Liabilities | $28.5M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | $4.3M | 2024-06-30 | 2025-09-04 | 10-K | 25-000068 |
| 22 | interest expense | us-gaap:InterestExpense | -$430,000 | 2024-06-30 | 2024-08-28 | 10-K | 24-000073 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.6M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $11.9M | 2025-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.4M | 2025-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $12.2M | 2024-06-30 | 2025-09-04 | 10-K | 25-000068 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.2M | 2024-06-30 | 2025-09-04 | 10-K | 25-000068 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $6.8M | 2023-06-30 | 2024-08-28 | 10-K | 24-000073 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.1M | 2023-06-30 | 2024-08-28 | 10-K | 24-000073 |
| 30 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $2.8M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 31 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $6.1M | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 32 | income tax | us-gaap:IncomeTaxExpenseBenefit | $994,000 | 2026-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 33 | current assets | us-gaap:AssetsCurrent | $50.9M | 2025-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $27.2M | 2025-06-30 | 2026-08-27 | 10-K | 26-371257 |
| 35 | assets | us-gaap:Assets | $60.3M | 2024-06-30 | 2025-09-04 | 10-K | 25-000068 |
| 36 | assets | us-gaap:Assets | $66.1M | 2023-06-30 | 2024-08-28 | 10-K | 24-000073 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 12,527,348 | 2026-08-26 | 2026-08-27 | 10-K | 26-371257 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 12,691,009 | 2025-09-03 | 2025-09-04 | 10-K | 25-000068 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.